Last reviewed · How we verify
CPL207280
CPL207280 is a small molecule that targets the SGLT2 receptor.
CPL207280 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CPL207280 |
|---|---|
| Sponsor | Celon Pharma SA |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, CPL207280 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes (PHASE2)
- Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPL207280 CI brief — competitive landscape report
- CPL207280 updates RSS · CI watch RSS
- Celon Pharma SA portfolio CI